Pharma Innovation - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Pharma Innovation
A look at the year's leaders in innovation strategy, including the top bio/pharmaceutical companies and award recipients from AAPS, PhRMA, and CPhI.


Pharmaceutical Technology
Volume 36, Issue 12

STUDENT INNOVATION ACROSS THE PHARMA SCIENCES

At the 2012 American Association of Pharmaceutical Scientists (AAPS) Annual Meeting in Chicago, graduate students across the country were honored for their research and work in bio/pharmaceutical innovation. Symposium awards were given to graduate students in the areas ranging from analysis and pharmaceutical quality to ocular drug delivery and disposition. Pharmaceutical Technology had the chance to talk with a few of the recipients about their work.

Biotechnology category winner David W. Woessner noted that his team's work at the University of Utah on "Synthetically Lethal Combinations for Chronic Myeloid Leukemia (CML) Therapy-Disrupting Dimerization of Bcr-Abl and Secondary Leukemia Specific Pathways" demonstrates the first development of a protein/peptide-based therapeutic for CML.

"While current therapies in the clinic (tyrsosine kinase inhibitors [TKIs]) act on the ABL portion of the protein, we are demonstrating efficacy by targeting the BCR portion, necessary for oligomerization and activation of the tyrosine kinase. Additionally, this work also exploits a combination therapy approach early in development," he said. Future research in this area has already moved towards combination therapy approaches, explained Woessner. "There are now essentially five TKIs that effectively treat CML. Combinations with other small molecules that target leukemic stem cells, but not normal/healthy hematopoietic stem cells are highly valued. We will continue to see trials for drug combinations," he said.

Mamta Kapoor of the University of Connecticut also won in the biotechnology category. Her research, "Elucidation of Cellular Uptake Mechanism of Novel Ternary Anionic-siRNA Lipoplexes," aimed to obtain an understanding on formulation-cell interaction that may facilitate faster formulation optimization to achieve efficient delivery. "This research area is interesting because it involves a mechanistic approach to comprehend the rate-limiting steps to proficient intracellular delivery of therapeutic agents," Kapoor explained. The mechanistic studies "have helped in understanding the contribution of formulation components in the uptake process and consequent bioactivity." Looking ahead, Kapoor's team intends to repeat the studies with other novel formulations.

Lakshmi Prasanna Kolluru, who won in the drug design and development interface category, focused on the "Design and Development of Albumin-based Theragnostic Nanoparticles for Tumor Targeted Drug Delivery." Based at Mercer University, the PhD candidate was inspired as a teenager by a cousin, a cancer patient suffering from the side effects of chemotherapy. "She was disturbed psychologically when she had lost her hair due to side effects and this spurred the interest in me to focus on cancer research. So, when my professor gave me the freedom to design a project, I opted to work on development of a delivery system that targets anti cancer drugs to tumor and reduces the side-effects of chemotherapy," said Kolluru. Looking ahead, the grad student says the university team is "planning to decorate this delivery system with dual-targeting probes to examine the efficacy of the targeting ligands in vitro and in vivo for selective localization of the drug in the tumor region."

Jiban Jyoti Panda of the International Center for Genetic Engineering and Biotechnology in New Delhi and of the FM University of Balasore, Odisha, India, won in the category of formulation design and development for the paper, "Self-Assembled Dipeptide Nanotubes, Nanovesicles and Nanogels: Potential Vehicles for Targeted Tumor Drug Delivery." The research focused on testing the potential of nanotechnology in cancer therapy. "Different types of polymeric, inorganic, and metallic nanoparticles have been investigated for their potential for effective tumor delivery and therapy. However, there are many factors which prevent the development of these nanoparticles for safe human use," Panda explained. "We tried to develop peptide-based nanoparticles, which are expected to be highly biocompatible due to their peptidic origin. Moreover, because the greatest problem with peptide-based drugs or systems is their low in vivo stability, we tried to develop nanoparticles from designed small peptides with the modified amino acid a, -dehydrophenylalanine (?Phe), residue, which is unique and would provide the nanostructures with enhanced assembling behavior and resistance to enzymatic degradation leading to better stability."


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
24%
Oversee medical treatment of patients in the US.
12%
Provide treatment for patients globally.
10%
All of the above.
44%
No government involvement in patient treatment or drug development.
10%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Source: Pharmaceutical Technology,
Click here